IN2012DN04908A - - Google Patents

Download PDF

Info

Publication number
IN2012DN04908A
IN2012DN04908A IN4908DEN2012A IN2012DN04908A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A IN 4908DEN2012 A IN4908DEN2012 A IN 4908DEN2012A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A
Authority
IN
India
Prior art keywords
antibody
disclosed
antibodies
expressing cells
drug conjugates
Prior art date
Application number
Inventor
Michel Pierres
Eric Vivier
Myriam Baratin
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN04908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of IN2012DN04908A publication Critical patent/IN2012DN04908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells.
IN4908DEN2012 2009-12-09 2010-12-08 IN2012DN04908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28501809P 2009-12-09 2009-12-09
PCT/IB2010/003411 WO2011070443A1 (en) 2009-12-09 2010-12-08 Monoclonal antibodies that bind b7h6 and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN04908A true IN2012DN04908A (en) 2015-09-25

Family

ID=43827827

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4908DEN2012 IN2012DN04908A (en) 2009-12-09 2010-12-08

Country Status (18)

Country Link
US (2) US8822652B2 (en)
EP (1) EP2510011B2 (en)
JP (2) JP2013513380A (en)
CN (2) CN104926942B (en)
BR (1) BR112012013975B8 (en)
CA (1) CA2783740C (en)
DK (1) DK2510011T3 (en)
EA (1) EA024629B1 (en)
ES (1) ES2523472T3 (en)
HR (1) HRP20141170T1 (en)
IN (1) IN2012DN04908A (en)
MX (1) MX2012006443A (en)
PL (1) PL2510011T3 (en)
PT (1) PT2510011E (en)
RS (1) RS53667B1 (en)
SI (1) SI2510011T1 (en)
SM (1) SMT201400184B (en)
WO (1) WO2011070443A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
PT2510011E (en) 2009-12-09 2014-12-12 Inst Nat Santé Et De La Rech Médicale Monoclonal antibodies that bind b7h6 and uses thereof
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CA2848333A1 (en) * 2011-09-13 2013-03-21 Deutsches Krebsforschungszentrum B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide
CN110511278B (en) * 2012-05-07 2024-08-09 达特茅斯大学理事会 Anti-B7-H6 antibodies, fusion proteins, and methods of use thereof
EP2711707A1 (en) 2012-09-21 2014-03-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to chemotherapy
WO2014044799A1 (en) * 2012-09-21 2014-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides
CN114634569B (en) * 2016-04-15 2024-08-20 达特茅斯大学理事会 High affinity B7-H6 antibodies and antibody fragments
US11191771B2 (en) * 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
EP3710481A4 (en) * 2017-11-16 2021-08-18 Antigenesis LLC SYSTEMS AND METHODS FOR LYSOSOME-INDUCED DEATH OF IMMUNOGENOUS CELLS
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US20240376195A1 (en) * 2020-01-17 2024-11-14 Beigene, Ltd. ANTI-NKp30 ANTIBODIES AND METHODS OF USE
IL305847A (en) 2021-03-26 2023-11-01 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
MX2023014647A (en) 2021-06-09 2024-01-31 Innate Pharma MULTI-SPECIFIC NKP46 BINDING PROTEINS.
CN114395045B (en) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7H6 antibody and its application
CN114395043B (en) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 NCR3LG1 antibody and application thereof
CN114395047B (en) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 Bispecific antibodies and uses thereof
CN114395044B (en) * 2021-12-07 2023-12-29 合肥天港免疫药物有限公司 Recombinant antibodies and uses thereof
CN114634574B (en) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 Anti-B7H6 scFv antibody, its encoding gene and its application
KR20240003756A (en) * 2022-06-29 2024-01-09 고려대학교 산학협력단 B7H6 variants with enhanced binding to NKp30
CN120265755A (en) * 2022-11-16 2025-07-04 德国癌症研究公共权益基金会 T cell-NK cell interaction inhibitors for disease treatment
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4883662A (en) 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
DE68921982T4 (en) 1988-06-14 1996-04-25 Cetus Oncology Corp COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
JP3202999B2 (en) 1991-01-31 2001-08-27 協和醗酵工業株式会社 Hepatic liposome preparation
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
DK0871490T3 (en) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Branched hydrazone linkers
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
DE69832158T2 (en) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe ISOLATION AND STRUCTURAL EXPLANATION OF CRYOSTATIC LINEARS AND CYCLO DEPSIPEPTIDES DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2001051514A1 (en) * 2000-01-07 2001-07-19 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004022594A2 (en) * 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
JP2008540569A (en) * 2005-05-12 2008-11-20 ザイモジェネティクス， インコーポレイテッド Methods of using pNKp30, a B7 family member, to modulate the immune system
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
JP5496897B2 (en) * 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド B7 family member zB7H6 and related compositions and methods
PT2510011E (en) 2009-12-09 2014-12-12 Inst Nat Santé Et De La Rech Médicale Monoclonal antibodies that bind b7h6 and uses thereof

Also Published As

Publication number Publication date
CA2783740C (en) 2020-03-10
WO2011070443A1 (en) 2011-06-16
BR112012013975B8 (en) 2021-05-25
CN104926942A (en) 2015-09-23
EP2510011A1 (en) 2012-10-17
BR112012013975B1 (en) 2021-01-12
EP2510011B1 (en) 2014-09-17
RS53667B1 (en) 2015-04-30
SI2510011T1 (en) 2014-12-31
CN102741290B (en) 2015-04-22
CN104926942B (en) 2018-09-14
HRP20141170T1 (en) 2015-01-30
US9663577B2 (en) 2017-05-30
JP2017031147A (en) 2017-02-09
JP6212181B2 (en) 2017-10-11
EP2510011B2 (en) 2021-03-31
PT2510011E (en) 2014-12-12
EA024629B1 (en) 2016-10-31
BR112012013975A2 (en) 2017-01-10
DK2510011T3 (en) 2014-12-01
CN102741290A (en) 2012-10-17
SMT201400184B (en) 2015-01-15
CA2783740A1 (en) 2011-06-16
US8822652B2 (en) 2014-09-02
MX2012006443A (en) 2012-06-28
PL2510011T3 (en) 2015-02-27
EA201270654A1 (en) 2013-02-28
US20130004432A1 (en) 2013-01-03
US20150056214A1 (en) 2015-02-26
ES2523472T3 (en) 2014-11-26
JP2013513380A (en) 2013-04-22

Similar Documents

Publication Publication Date Title
IN2012DN04908A (en)
IL287292A (en) Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
EA201070463A1 (en) COMBINED THERAPY WITH THE USE OF ANTIBODY AND MEDICINE CONJUGATES
NO20084356L (en) Anti TAT226 antibodies and immunoconjugates
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
MY170719A (en) Antibody-drug conjugates
NZ602220A (en) Antibodies with ph dependent antigen binding
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2009014708A3 (en) Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CY1116261T1 (en) ANTIBODIES AND IMMUNITIES AND THEIR USES
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
WO2012087962A3 (en) Anti-mesothelin antibodies and immunoconjugates
WO2009046407A3 (en) B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
UA107574C2 (en) Humanized antibody specific to the protofibrillar form of the beta-amyloid peptide
MY197840A (en) Cross-linkers and their uses
IL218740A0 (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
IL214983A0 (en) Antibody drug conjugated that bind monomethyl auristatin e (mmae), compositions comprisimg the same and uses thereof
NZ616382A (en) Antibodies specific to cadherin-17
AU2011343161A8 (en) Human anti-SOD1 antibodies
MX2012009564A (en) Integrin î±vî²8 neutralizing antibody.
MX2009005103A (en) Anti-idiotype conjugate and its use as a standard in an immunassay.
EP2519542A4 (en) Anti-cdh3 antibodies and uses thereof
CY1116022T1 (en) Monoclonal antibodies that block TON B7H6 and their uses
HK1172899A (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody